Bioindustry welcomes new French legislation covering biosimilar medicines
The law confirms the EU legal definition of a "biosimilar" medicine and recognises the uniqueness of this new generation of products. It states that they cannot be classified as "generics" in the same way that chemical compounds may be, due to the differences stemming from the variability of the active biotechnological substance and its manufacturing process.
Commenting on the adoption of the new legislation, EuropaBio's Chair of the Healthcare Council, Andrea Rappagliosi said "We strongly appreciate the efforts made by the French government in pursuing a patient-centred vision by promoting innovation in healthcare".
The ban on the automatic substitution of one biological medicine over another reinforces the central role of the physician-patient relationship that is mandatory in order to deliver the most effective treatment to an individual patient when using biotech-derived therapies.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.